Tag Archives: amyloidosis

Professor Christopher Miller HFpEF on the rise: navigating the heterogeneity In an engaging opening talk, Professor Christopher Miller (University of Manchester) revealed heart failure with preserved ejection fraction (HFpEF) as the dominant form of heart failure (HF), rising by 10% every decade. Over 70% of patients with HF have HFpEF, most of whom are over 65 years of age experiencing complex comorbidities. The diagnostic challenges in heterogeneous groups were discussed against the background of the diagnostic criteria provided by European Society of Cardiology (ESC)1 as some patients with clinical signs of HFpEF show normal

Tafamidis – a new treatment for amyloidosis The European Commission (EC) has granted marketing authorisation for tafamidis (Vyndaqel®, Pfizer), a once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Tafamidis is the first authorised treatment in the European Union for patients with ATTR-CM. Prior to this authorisation, treatment options for patients with ATTR-CM were restricted to symptom management, and, in rare cases, heart (or heart and liver) transplant. ATTR-CM is a rare, under-diagnosed and life-threatening disease characterised by the b